Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
24 hedge funds and large institutions have $50M invested in Albireo Pharma Inc in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
102% more capital invested
Capital invested by funds: $24.8M → $50M (+$25.2M)
41% more funds holding
Funds holding: 17 → 24 (+7)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$17.3M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$4.1M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$3.46M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.12M |
| 5 |
Millennium Management
New York
|
+$615K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$876K |
| 2 |
Renaissance Technologies
New York
|
-$86.2K |
| 3 |
SCM
Segantii Capital Management
Hong Kong
|
-$51K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
-$14K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$12.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| – | -$5.01K | -244 | -100% |
|
ALBO Hedge Fund Activity: Q2 2017 in Review
24 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2017, worth a combined $50M — up 102% from $24.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ALBO positions and 4 closed out — a net gain of 7 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $17.3M. The largest seller was Opaleye Management, exiting entirely with an estimated $876K sold.
- 24 institutional investors held Albireo Pharma Inc (ALBO) as of Q2 2017, up from 17 in Q1 2017.
- Funds reported $50M of Albireo Pharma Inc stock for Q2 2017, up 102% quarter-over-quarter.
- 11 funds opened new Albireo Pharma Inc positions in Q2 2017 and 4 closed out, a net change of +7 holders.
- The largest Albireo Pharma Inc buyer in Q2 2017 was Perceptive Advisors, an estimated $17.3M added.
- The largest Albireo Pharma Inc seller in Q2 2017 was Opaleye Management, an estimated $876K sold.
Based on aggregated 13F filings for Q2 2017.